Lupin launches Mirabegron ER tablets in US

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development

Lupin launches Doxorubicin Hydrochloride Liposome Injection in US

ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain

Birajeev is a seasoned Supply Chain leader with an experience of 23 years

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Govt. to improve availability of infrastructure and trained manpower for organ transplantation

Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country

Biocon Pharma receives USFDA approval for daptomycin

The approval further adds to Biocon’s portfolio of complex drug products

Zydus receives USFDA final approval for Scopolamine Transdermal System 1 mg/3 days

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025